Roivant (ROIV) Director Meghan Fitzgerald Exercises Options, Sells Shares

What Happened Meghan Fitzgerald, a director of Roivant Sciences (ROIV), exercised options to acquire 20,000 common shares at $8.80 per share (paying $176,000) on 2026-09-08, and on the same date sold 20,000 shares in the open market at a weighted average price of $39.90 (proceeds ≈ $798,000). The filing also records a derivative disposition of 20,000 at $0 (see Key Details). The sale was executed pursuant to a Rule 10b5-1 trading plan.

Key Details

• Transaction date: 2026-09-08 (Period of Report); Form 4 filed 2026-09-10.
• Exercise (code M): 20,000 shares acquired at $8.80 each — total cost $176,000.
• Sale (code S): 20,000 shares sold at a weighted average $39.90 — proceeds ≈ $798,000; reported sale prices ranged $39.90–$40.00 (footnote F1).
• Derivative entry: 20,000 reported disposed at $0 (likely reflects conversion/settlement related to the option exercise); footnote F2 notes the options were fully vested.
• Shares owned after the transactions: not disclosed in the provided filing summary.
• Timing: Form filed two days after the transactions (appears timely). Sales were effected under a pre-established Rule 10b5-1 plan.

Context

• Code M = exercise/conversion of a derivative (option); Code S = sale of shares. Here the insider exercised options and immediately sold an equal number of shares, a common practice to monetize vested options or cover costs/taxes.
• Filing notes the sale prices were within a narrow range and were made under a 10b5-1 plan, which generally means the trades were pre-planned and not spontaneous.
• This report is factual disclosure of insider activity and does not itself indicate the insider’s future view of the company.